To date, many studies have investigated specific gene expression, gene signature, and excision repair cross-complementation group 1 (ERCC1), which is related to cisplatin (CDDP) sensitivity, as candidate biomarkers for adjuvant chemotherapy in patients with NSCLC [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.